Ann: Correction - Results of 2023 Annual General Meeting, page-3

Not sure if they are selling rapid antigen tests any longer - they certainly had a lot of expired stock, which they had to recognise as a loss. They made an error - one of several - some years back in deciding to rebrand imported stock, which required seperate TGA approval. As a consequence, they missed the opportunity to make quick sales. Having said this, the sales they did manage to make did provide the company with a good temporary buffer.

The changes in management and the board reflect the challenges faced by the company and the outcomes of the recent AGM.

So far, no significant news from the company. While I acknowledge that things take time, and that medical partnerships build long-term financial benefits, it would be good if the company could have a year of positive traction.